MA30631B1 - Inhibiteurs de tyrosine kinase - Google Patents

Inhibiteurs de tyrosine kinase

Info

Publication number
MA30631B1
MA30631B1 MA31620A MA31620A MA30631B1 MA 30631 B1 MA30631 B1 MA 30631B1 MA 31620 A MA31620 A MA 31620A MA 31620 A MA31620 A MA 31620A MA 30631 B1 MA30631 B1 MA 30631B1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitors
met
treating
cyclohepta
Prior art date
Application number
MA31620A
Other languages
English (en)
Inventor
Christopher J Dinsmore
Matthew H Katcher
Alan B Northrup
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA30631B1 publication Critical patent/MA30631B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des dérivés de 5H-benzo[4,5]cyclohepta [1,2-b]pyridine, qui sont utiles pour traiter des maladies de prolifération cellulaire, pour traiter les troubles associés à l'activité de MET, et pour l'inhibition du récepteur tyrosine kinase MET. L'invention concerne aussi des compositions qui comprennent ces composés, et des procédés pour les utiliser pour traiter le cancer chez des mammifères.
MA31620A 2006-07-10 2009-02-09 Inhibiteurs de tyrosine kinase MA30631B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81976406P 2006-07-10 2006-07-10

Publications (1)

Publication Number Publication Date
MA30631B1 true MA30631B1 (fr) 2009-08-03

Family

ID=38923821

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31620A MA30631B1 (fr) 2006-07-10 2009-02-09 Inhibiteurs de tyrosine kinase

Country Status (24)

Country Link
US (2) US8222269B2 (fr)
EP (1) EP2049494B1 (fr)
JP (2) JP4203121B1 (fr)
KR (1) KR20090026187A (fr)
CN (1) CN101535268B (fr)
AR (1) AR061804A1 (fr)
AU (1) AU2007273081B2 (fr)
BR (1) BRPI0713941A2 (fr)
CA (1) CA2656578C (fr)
CO (1) CO6190518A2 (fr)
CR (1) CR10560A (fr)
EC (1) ECSP099051A (fr)
ES (1) ES2497493T3 (fr)
GT (1) GT200900004A (fr)
HN (1) HN2009000018A (fr)
IL (1) IL196337A0 (fr)
MA (1) MA30631B1 (fr)
MX (1) MX2009000410A (fr)
NO (1) NO20090608L (fr)
PE (1) PE20080275A1 (fr)
RU (1) RU2009104303A (fr)
TW (1) TW200813021A (fr)
WO (1) WO2008008310A2 (fr)
ZA (1) ZA200900019B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002254A2 (fr) 2005-06-23 2007-01-04 Merck & Co., Inc. Benzocycloheptapyridines utilises comme inhibiteurs de la tyrosine kinase receptrice met
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors
US20110065578A1 (en) * 2008-05-21 2011-03-17 Basf Se Substituted Pyridin-4-ylmethyl Sulfonamides
AU2010300930B2 (en) * 2009-09-30 2014-09-11 Merck Sharp & Dohme (Uk) Limited Crystalline hydrochloride salts of c-MET kinase inhibitors
JP5775085B2 (ja) * 2009-09-30 2015-09-09 メルク シャープ エンド ドーム リミテッド ｃ−ＭＥＴキナーゼ阻害剤の製剤
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
EP3027654B1 (fr) 2013-07-30 2019-09-25 Blueprint Medicines Corporation Fusions de pik3c2g
EP3628749A1 (fr) * 2013-07-30 2020-04-01 Blueprint Medicines Corporation Fusions de ntrk2
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ａｘｌに対するヒトモノクローナル抗体
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
CA3027705A1 (fr) * 2016-06-17 2017-12-21 The Trustees Of The University Of Pennsylvania Composes et methodes pour la prevention et/ou le traitement du cancer
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (fr) * 1963-04-24
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
IE68935B1 (en) 1990-06-22 1996-07-24 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use
US6365588B1 (en) * 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1997014672A1 (fr) * 1995-10-16 1997-04-24 Kyowa Hakko Kogyo Co. Ltd. Composes tricycliques
ATE294172T1 (de) 1996-09-13 2005-05-15 Schering Corp Substituierte benzocycloheptapyridine derivate verwendbar als farnesyl-protein transferase inhibitoren
BR9712819A (pt) 1996-09-13 1999-11-23 Schering Corp Compostos tricìclicos úteis para inibição de função de proteìna g e para tratamento de doenças proliferativas
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
AU2003230758A1 (en) 2002-04-02 2003-10-20 Merck And Co., Inc. 5h-benzo(4,5)cyclohepta(1,2-b)pyridine nmda/nr2b antagonists
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ES2211315B1 (es) 2002-11-12 2005-10-16 Almirall Prodesfarma, S.A. Nuevos compuestos triciclicos.
JP2006151809A (ja) 2002-12-26 2006-06-15 Ube Ind Ltd ベンゾシクロヘプタピリジン化合物
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
TW200738638A (en) * 2005-06-23 2007-10-16 Merck & Co Inc Tyrosine kinase inhibitors
WO2007002254A2 (fr) * 2005-06-23 2007-01-04 Merck & Co., Inc. Benzocycloheptapyridines utilises comme inhibiteurs de la tyrosine kinase receptrice met

Also Published As

Publication number Publication date
CN101535268B (zh) 2012-11-14
NO20090608L (no) 2009-04-14
BRPI0713941A2 (pt) 2012-12-04
ES2497493T3 (es) 2014-09-23
US8101603B2 (en) 2012-01-24
MX2009000410A (es) 2009-01-27
CA2656578A1 (fr) 2008-01-17
JP5245045B2 (ja) 2013-07-24
RU2009104303A (ru) 2010-08-20
KR20090026187A (ko) 2009-03-11
IL196337A0 (en) 2009-09-22
GT200900004A (es) 2010-04-13
PE20080275A1 (es) 2008-04-03
US20090012076A1 (en) 2009-01-08
ECSP099051A (es) 2009-02-27
WO2008008310A2 (fr) 2008-01-17
JP4203121B1 (ja) 2008-12-24
AU2007273081A1 (en) 2008-01-17
ZA200900019B (en) 2009-11-25
HN2009000018A (es) 2011-01-24
US8222269B2 (en) 2012-07-17
CA2656578C (fr) 2012-09-04
JP2009173622A (ja) 2009-08-06
EP2049494A2 (fr) 2009-04-22
US20090203684A1 (en) 2009-08-13
JP2009512698A (ja) 2009-03-26
CR10560A (es) 2009-02-26
EP2049494B1 (fr) 2014-06-25
AR061804A1 (es) 2008-09-24
CO6190518A2 (es) 2010-08-19
AU2007273081B2 (en) 2011-04-07
CN101535268A (zh) 2009-09-16
WO2008008310A3 (fr) 2008-05-15
TW200813021A (en) 2008-03-16

Similar Documents

Publication Publication Date Title
MA30631B1 (fr) Inhibiteurs de tyrosine kinase
MA29643B1 (fr) Benzocycloheptapyridines comme inhibiteurs du recepteur tyrozine kinase met
SI1896421T1 (sl) Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met
WO2007149427A3 (fr) Inhibiteurs de tyrosine kinase
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
YU84603A (sh) Novi inhibitori tirozin kinaze
MA31442B1 (fr) 3-(imidazolyl)-pyrazolo [3,4-b]pyridines
EP1463733A4 (fr) Inhibiteurs de kinesine mitotique
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
WO2003049678A3 (fr) Inhibiteurs mitotiques de la kinesine
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2003039460A3 (fr) Inhibiteurs de la kinesine mitotique
WO2006124354A3 (fr) Inhibiteurs de la tyrosine kinase
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
IL165624A0 (en) Mitotic kinesin inhibitors
WO2004058148A3 (fr) Inhibiteurs de la kinesine mitotique
MA29561B1 (fr) DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
WO2005060654A3 (fr) Inhibiteurs de kinesines mitotiques
WO2007118151A3 (fr) Dérivés spirocycliques hétérocycliques et procédés pour leur utilisation
MXPA04010307A (es) Derivados 5-oxo y 5-tio de 5h-indeno`1,2-bipiridina con enlace al receptor a2a de la adenosina y actividad inhibidora de la fosfodiesterasa para el tratamiento de trastornos neurodegenerativos y enfermedades relacionadas con la inflamacion.
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
WO2006068933A3 (fr) Inhibiteurs de la kinesine mitotique
WO2007050380A3 (fr) Inhibiteurs de la tyrosine kinase